Revolution Medicines (RVMD)
Health Care · Clinical-stage precision oncology
A precision oncology biotech in clinical development stages, pursuing targeted cancer therapies with no approved products yet but backed by substantial capital.
What Revolution Medicines does
Revolution Medicines is a clinical-stage precision oncology company developing novel targeted therapies for cancer patients. The company focuses on discovering and developing product candidates intended to address various oncology indications. With a limited operating history and no products yet approved for commercial sale, Revolution Medicines is currently conducting preclinical and clinical development activities and has not yet generated any revenue from product sales.
Themes: ["oncology / cancer therapeutics"]
Fundamentals
- Price$191.13 as of 2026-07-09 close
- Market cap$40.9B as of 2026-07-10
- 1-year return+396.2% as of 2026-07-09 close
- Net margin-2833.9% as of 2026-07-10
- ROE-54.1% as of 2026-07-10
- Debt / equity0.19 as of 2026-07-10
- Beta1.41 as of 2026-07-10
Key risks (from latest filing)
["Clinical-stage company with no approved products and no product revenue; significant risk of failure to complete clinical trials or obtain regulatory approval"]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.